BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
Go back to BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM| (NASDAQ: BBIO) | Delayed: 75.15 +0.31 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $74.84 | 52 Week High | $ | |||
| Open | $73.60 | 52 Week Low | $ | |||
| Day High | $76.34 | P/E | N/A | |||
| Day Low | $73.26 | EPS | $ | |||
| Volume | 558,448 | |||||
